Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UPLIFT reassures some over Spiriva CV safety

This article was originally published in Scrip

Executive Summary

Boehringer Ingelheim/Pfizer's leading COPD treatment Spiriva (tiotropium bromide) failed to reduce the rate of decline in FEV1 over four years of treatment, the results of the large, long-term UPLIFT study show, but the researchers have found positive effects from the drug and the data have provided some reassurance over the its cardiovascular safety, the subject of great scrutiny in recent weeks.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC030478

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel